{"id":"bay86-5016-sh-p00331f","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL585625","moleculeType":"Small molecule","molecularWeight":"388.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a direct thrombin inhibitor, BAY86-5016 binds to and inactivates Factor IIa (thrombin), a key serine protease in the coagulation cascade responsible for converting fibrinogen to fibrin and amplifying clot formation. By selectively inhibiting thrombin's catalytic activity, the drug reduces thrombin-mediated platelet activation and fibrin generation, thereby preventing pathological thrombosis while maintaining hemostasis.","oneSentence":"BAY86-5016 is a Factor IIa (thrombin) inhibitor that directly blocks the active site of thrombin to prevent blood clot formation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:03:38.403Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome"},{"name":"Thromboembolism prevention"}]},"trialDetails":[{"nctId":"NCT00185354","phase":"PHASE3","title":"FC Patch Comparator Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-11","conditions":"Contraception","enrollment":422}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BAY86-5016, SH P00331F","genericName":"BAY86-5016, SH P00331F","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BAY86-5016, also known as SH P00331F, is a small molecule used in a clinical trial for contraception. It was studied in a multi-center trial, the FC Patch Comparator Study, as part of a comparison of cycle control for seven consecutive cycles.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}